Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting
approximately 20%-30% of the population in Western countries. Nonalcoholic …

Nonalcoholic fatty liver disease (NAFLD) is the most common initial presentation of obesity
and insulin resistance. Uninterrupted progression of hepatic lipid accumulation often leads …

The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor highly expressed
in liver and intestine, regulates the expression of genes involved in cholesterol and bile acid …

The nuclear receptors PPARα (encoded by NR1C1) and farnesoid X receptor (FXR,
encoded by NR1H4) are activated in the liver in the fasted and fed state, respectively …

Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from
simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. To date, no …

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and strongly associated
with central obesity, dyslipidemia, and insulin resistance. According to the multiple-hit model …

Non-alcoholic fatty liver disease (NAFLD) is characterized by the aberrant accumulation of
triglycerides in hepatocytes in the absence of significant alcohol consumption, viral infection …

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic
syndrome and is one of the most prevalent liver disorders worldwide. NAFLD can gradually …

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic
syndrome and a risk factor for both cardiovascular and hepatic related morbidity and …

Non-alcoholic fatty liver disease (NAFLD) is a common health problem with a high mortality
burden due to its liver-and vascular-specific complications. It is associated with obesity, high …